Table 2.
Characteristics of lymph nodes in the vaccine and metastasis groups
| Vaccine group (n = 41) | Metastasis group (n = 39) | P value | |
|---|---|---|---|
| Lymphadenopathy | |||
| Ventral | |||
| Presence (%) | 39 (95.1) | 38 (97.4) | |
| Absence (%) | 2 (4.9) | 1 (2.6) | 1a |
| Dorsal | |||
| Presence (%) | 16 (39.0) | 2 (5.1) | |
| Absence (%) | 25 (61.0) | 37 (94.9) | < 0.001*, a |
| Short diameter | |||
| Ventral | 6.4 mm (5.2–10.0) | 8.0 mm (5.5–22.5) | 0.004*, b |
| Dorsal | 6.0 mm (5.0–10.0) | 6.6 mm (5.8–7.4) | 0.673b |
| Long diameter | |||
| Ventral | 10.3 mm (5.6–24.9) | 14.1 mm (5.7–25.0) | < 0.001*, b |
| Dorsal | 10.3 mm (6.4–19.4) | 9.0 mm (8.8–9.2) | 0.325b |
| Shape | |||
| Ventral | |||
| Eccentric cortical thickening (%) | 27 (69.2) | 16 (42.1) | 0.068a |
| Round (%) | 4 (10.3) | 6 (15.8) | |
| Oval (%) | 8 (20.5) | 14 (36.8) | |
| Horseshoe shaped (%) | 0 (0.0) | 2 (5.3) | |
| Dorsal | |||
| Eccentric cortical thickening (%) | 13 (81.2) | 1 (50.0) | 0.405a |
| Round (%) | 1 (6.2) | 1 (50.0) | |
| Oval (%) | 2 (12.5) | 0 (0.0) | |
| Presence of fatty hilum | |||
| Ventral (%) | 21 (53.8) | 20 (52.6) | 1a |
| Dorsal (%) | 8 (50.0) | 1 (50.0) | 1a |
| Number of visible lymph nodes | |||
| Both areas | 15 (3–36) | 7 (1–18) | < 0.001*, b |
| Ventral | 10 (2–23) | 6 (1–15) | < 0.001*, b |
| Dorsal | 3 (0–13) | 1 (0–5) | < 0.001*, b |
Data are expressed as median (range)
*significant values
aFisher’s exact test
bMann–Whitney U test